The directed new share issue totals SEK 73 million before issue expenses.The present major shareholders H&B Capital, Christer Fåhraeus, Metallica and Företagskapital Kompanjonfonden are contributing SEK 40 million. Skandia Liv is entering as new institutional investor supplying SEK 25 million, which makes Skandia Livs the fifth largest shareholder. Other shareholders are subscribing for the remaining SEK 8 Mkr. The capital will be used to finance the continued introduction of the Company's product DiffMaster(TM) on the global market and further development of software applications and hardware platform.
"We are very pleased with the renewed confidence granted by our existing shareholders and to have Skandia Liv as a new institutional shareholder. This capital contribution enables us to select the optimal time for a future stock-market listing. CellaVision is undergoing a phase of extremely robust expansion. Next year we will commence sales outside the Nordic countries on key markets in Europe and through our subsidiary in the U.S.", says Yvonne Mårtensson, CEO, CellaVision AB.
"This successful new share issue confirms the qualities of CellaVision AB as a leading Swedish company within medical technology. The Company has managed to reach a commercial phase with its unique cutting-edge competence in medical image analysis", says Lars Gatenbeck, member of the CellaVision board and CEO, H&B Capital.
On the basis of the authorization granted by the Annual General Meeting of 2001, the Board of CellaVision AB (publ) resolved on December 14, 2001 to increase the Company's share capital by a maximum of SEK 398,410.50, with divergence from shareholders' preferential rights, through a new issue of a maximum of 2,656,070 shares with a par value of SEK 0.15. Holders of the new shares, which will be issued at a price of SEK 27.50 per share, will be entitled to dividends as of the fiscal year 2001. Subscription payment shall be effected by December 20, 2001 at the latest.
Present shareholders and/or institutional investors, who in accordance with an invitation to subscribe for shares notified their interest during the term December 3-13, have subscribed for the shares.